Laboratorios Farmaceuticos Rovi, S.A. (LON: 0ILL)

Laboratorios Farmaceuticos Rovi Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	17.55	25.32	124.95	99.04	53.16	67.43
Short-Term Investments	-	0.11	0.09	0.1	0.07	0.08
Cash & Short-Term Investments	17.55	25.44	125.03	99.14	53.23	67.51
Cash Growth	-68.86%	-79.66%	26.12%	86.22%	-21.14%	-29.37%
Accounts Receivable	185.51	124.55	160.23	129.8	63.34	71.67
Other Receivables	-	15.91	21.06	27.83	18.61	18.31
Receivables	185.51	140.46	181.28	157.63	81.95	89.98
Inventory	346.66	337.97	311.94	245.47	227.2	158.81
Prepaid Expenses	4.1	2.73	2.03	1.79	0.01	0
Other Current Assets	-	2.74	2.79	2.33	2.18	1.59
Total Current Assets	553.83	509.33	623.07	506.36	364.58	317.89
Property, Plant & Equipment	269.6	253.65	215.54	181.78	155.4	131.61
Long-Term Investments	19.58	0.59	2.2	2.07	1.88	1.91
Other Intangible Assets	32.66	27.74	29.14	31.51	33.93	37.15
Long-Term Deferred Tax Assets	2.12	2.34	2.08	3.85	11.11	14.66
Long-Term Deferred Charges	-	6.16	6.6	7.05	7.49	7.93
Other Long-Term Assets	0.07	0.07	0.07	0.07	0.07	0.07
Total Assets	877.85	799.88	878.7	732.68	574.44	511.21
Accounts Payable	124.27	109.6	125.87	99.4	65.19	70.07
Accrued Expenses	-	30.77	31.67	24.6	23.85	10.26
Current Portion of Long-Term Debt	34	8.06	8.27	2.98	2.95	9.24
Current Portion of Leases	-	5.13	4.46	3.44	3.07	3.46
Current Income Taxes Payable	27.78	5.26	-	0.68	-	-
Current Unearned Revenue	35.44	39.51	115.39	58.12	25.5	2.09
Other Current Liabilities	-	1.53	8.23	1.17	2.33	11.58
Total Current Liabilities	221.49	199.84	293.89	190.39	122.89	106.71
Long-Term Debt	78.2	38.58	46.04	52.52	53.94	54.69
Long-Term Leases	16.08	13.67	13.4	14.22	14.48	17.41
Long-Term Unearned Revenue	3.03	2.79	3.32	3.79	8.5	8.93
Long-Term Deferred Tax Liabilities	0.86	1.52	0.68	0.78	0.93	1.08
Total Liabilities	319.66	256.39	357.32	261.7	200.74	188.83
Common Stock	3.07	3.24	3.24	3.36	3.36	3.36
Additional Paid-In Capital	87.64	87.64	87.64	87.64	87.64	87.64
Retained Earnings	464.47	556.21	456.7	446.1	302.89	241.73
Treasury Stock	-6.48	-107.68	-27.56	-66.12	-20.19	-10.34
Comprehensive Income & Other	-0.03	-0.02	-0.01	-0	-0	-0
Total Common Equity	548.68	539.39	520.01	470.98	373.7	322.39
Minority Interest	9.51	4.11	1.37	-	-	-
Shareholders' Equity	558.19	543.49	521.38	470.98	373.7	322.39
Total Liabilities & Equity	877.85	799.88	878.7	732.68	574.44	511.21
Total Debt	128.28	65.43	72.17	73.16	74.44	84.81
Net Cash (Debt)	-110.72	-39.99	52.87	25.97	-21.21	-17.3
Net Cash Growth	-	-	103.55%	-	-	-
Net Cash Per Share	-2.07	-0.75	0.99	0.47	-0.38	-0.31
Filing Date Shares Outstanding	53.38	51.82	53.37	54.85	55.4	55.38
Total Common Shares Outstanding	53.38	51.82	53.37	54.85	55.4	55.38
Working Capital	332.34	309.49	329.19	315.97	241.69	211.18
Book Value Per Share	10.28	10.41	9.74	8.59	6.75	5.82
Tangible Book Value	516.02	511.65	490.87	439.46	339.77	285.24
Tangible Book Value Per Share	9.67	9.87	9.20	8.01	6.13	5.15
Land	-	60.65	45.12	37.25	35.75	35.34
Machinery	-	372.97	303.78	275.44	250.22	222.68
Construction In Progress	-	8.47	40.17	28.06	14.68	-

Source: S&P Capital IQ. Standard template. Financial Sources.